(infographic) Gigglebit is Siliconrepublics daily dose of the funny and fantastic in science and tech, to help start your day on a lighter note. Like any sector, technology has a serious side, and it is often issues within this serious side that make headlines or that organisations need to explore for their business. Malware! Data breaches! Cloud storage!
For the original version including any supplementary images or video, visit http://www.siliconrepublic.com/digital-life/item/38310-gigglebit-what-type-of/
CLEAN-TAVI Trial Shows Claret Medical Cerebral Protection System Dramatically Reduces Brain Lesions and Neurological Events Following Transcatheter Aortic Valve Replacement (TAVR) | Business Wire
The trial results showed a 53 percent reduction in the total volume of new brain lesions and a 60 percent reduction in the number of new brain lesions tips in installing home security systems two days after the procedure. The results were reported today by Professor Axel Linke, MD in a Late Breaking Clinical Trial session at the 26th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation. At two days post-TAVR in the Intent to Treat analysis, a neurological deficit was observed in 28 percent of all control patients when evaluated by a NIHSS (National Institute of Health Stroke Scale) trained specialist, demonstrating that prospective assessment pre- and post-procedure can identify more neurological effects than has been reported to date. However, importantly, the Per Protocol analysis at two days showed a statistically significantly lower ataxia rate of 24 percent versus nine percent in favor of the treatment group protected with the Claret Medical technology. The results seen with the Claret Medical system are striking, said Professor Axel Linke, MD, of the University of Leipzig, principal investigator for CLEAN-TAVI. They clearly show that by removing embolic debris from cerebral circulation when performing TAVR we can dramatically reduce both the quantity and volume of brain lesions. The CLEAN-TAVI outcomes validate our expectations that filter-based cerebral protection has the potential to improve neurological outcomes and enable a safer TAVR procedure, which will be necessary for the procedure to expand to lower risk populations, said Claret Medical Chief Executive Officer and President Azin Parhizgar, PhD. CLEAN-TAVI is a prospective, double blinded, 1:1 randomized controlled trial enrolling 100 patients indicated for transfemoral aortic valve implantation with the Medtronic CoreValve, where the Claret system was used for cerebral protection.
For the original version including any supplementary images or video, visit http://www.businesswire.com/news/home/20140913005006/en#.VBarDbFwbcs